(R) -Avanafil

• Description:

  (R) -Avanafil ((R) -TA1790) is a selective PDE5 inhibitor (IC50: 5.2 nM) . (R) -Avanafil can be used for research of erectile dysfunction[1].

• Product Name Alternative:

  (R) -TA1790

• UNSPSC:

  12352005

• Hazard Statement:

  H315-H319-H320

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/r-avanafil.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=C(Cl)C=C(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@@H](CO)CCC4)=N2)C=C1

• Molecular Formula:

  C23H26ClN7O3

• Molecular Weight:

  483.95

• Precautions:

  P264-P280-P302+P352-P305+P351+P338-P362

• References & Citations:

  [1]Sakamoto T, et al. The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor. Bioorg Med Chem Lett. 2014 Dec 1;24 (23) :5460-5.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1638497-26-3]